NOVARTIS, NVA237 ready to enter LAMA market: Spiriva domination under threat!!
NVS today announced the top-line results from its second pivotal PhIII trial (GLOW2) on NVA237 (once daily LAMA), meeting both, primary and the secondary endpoints. NVA237 demonstrated comparable safety and efficacy data vs. PFE’s Spiriva (once daily LAMA). Faster onset of action (5 min vs 20-30 min in tiotropium), higher selectivity for the muscarinic type-3 (M3) receptor which might potentially translated in to reduced antimuscarinic side effects is potentially how, NVS might pitch NVA237 against Spiriva. We expect NVA237 to garner upto 25% of the LAMA market growing approximately at 25%...
COMPANIES MENTIONED
NOVARTIS
NOVARTIS
